Toulouse

• A 12-Month Study of Lasmiditan (LY573144) Treatment in Children Aged 6 to 17 With Migraine (PIONEER-PEDS2) Ended
  2023-506724-85-00 5 2020-11-19 Migraine
• Primary Progressive Multiple Sclerosis (PPMS) Study of Bruton's Tyrosine Kinase (BTK) Inhibitor tolebrutinib (SAR442168) (PERSEUS) Ended
  2024-514495-41-00 5 2020-11-04 Primary Progressive Multiple Sclerosis
• A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of Ravulizumab in Adult and Adolescent Participants who have Thro … Ended
  2023-510107-22-00 5 2020-10-27 Hematopoietic stem cell transplant-associated thrombotic microangiopat
• IFCT-1802 SAVIMMUNE: Immunotherapy in Patient With Poor General Condition Ended
  2024-515943-44-00 4 2020-10-14 Non small cell lung cancer
• A Phase I, First In Human, open-label study of escalating doses of INA03 administered intravenously as single agent in adult patients with r … Ended
  2024-518265-10-01 1 2020-06-03 Relapse/ refractory acute Leukemia
• Pragmatic management of progressive disease in idiopathic pulmonary fibrosis Ended
  2024-511427-34-00 5 2020-02-20 idiopathic pulmonary fibrosis
• Olaparib Plus Pembrolizumab Compared to Chemotherapy Plus Pembrolizumab After Initial Treatment With Chemotherapy Plus Pembrolizumab in Trip … Ended
  2022-500418-24-00 10 2020-01-17 Locally Recurrent Inoperable or Metastatic Triple Negative Breast Canc
• Tepotinib plus osimertinib in osimertinib-relapsed MET amplified NSCLC Ended
  2024-512005-87-00 4 2019-11-07 Lung Cancer
• A multicentre phase II, open-label, non-randomized study evaluating Platinum-Pemetrexed-Atezolizumab ( Bevacizumab) for patients with stage … Ended
  2024-516201-23-00 4 2019-08-26 Lung Cancer, NSCLC
• Phase 3 Study of Pembrolizumab plus Enzalutamide in mCRPC Ended
  2022-500785-10-00 5 2019-08-23 Metastatic Castration-Resistant Prostate Cancer
• Phase 3b/4 Study in Rheumatoid Arthritis Ended
  2023-508022-10-00 6 2019-07-25 Rheumatoid Arthritis
• Comparative multicenter randomized study of aflibercept versus placebo in macular telangiectasia type 1 Ended
  2024-511885-35-00 5 2019-07-03 macular telangiectasia type 1
• Dexamethasone in Herpes Simplex Virus Encephalitis Open label Randomized Controlled Trial with an Observer-blinded evaluation at 6 months Ended
  2024-515985-16-00 5 2019-04-25 Herpes Simplex Virus Encephalitis
• A safety and efficacy study of ABT-494 in subjects with Giant Cell Arteritis. Ended
  2023-505476-29-00 5 2019-04-05 Giant Cell Arteritis
• Pembrolizumab as adjuvant therapy for resectable high-risk LA cSCC Ended
  2022-500395-57-00 5 2019-03-04 Resectable high-risk Locally Advanced Cutaneous Squamous Cell Carcinom
• Evaluation of Upadacitinib in Adolescent and Adult Patients with Moderate to Severe Atopic Dermatitis (Eczema)– Measure Up 1 Ended
  2022-502938-30-00 5 2018-12-10 Moderate and Severe Atopic Dermatitis
• Trial comparing the continuation of nivolumab and ipilimumab (doublet immunotherapy) to observation after a first 6 months treatment by nivo … Ended
  2024-514586-20-01 5 2018-05-02 Non small cell lung cancer
• Predictive factors and magnitude of response to omalizumab and mepolizumab in allergic and eosinophilic severe asthma: PREDICTUMAB, an open- … Ended
  2024-516783-29-00 6 2018-04-16 Severe allergic and eosinophilic asthma
• A Study of Erdafitinib Compared with Vinflunine or Docetaxel or Pembrolizumab in Subjects with Urothelial Cancer Ended
  2023-510296-56-00 5 2018-03-26 Advanced Urothelial Cancer
• Interest of Intra-nodal injection of gentamicin for the treatment of suppurated cat scratch disease's lymphadenitis Ended
  2024-512037-32-00 5 2017-05-31 Bartonellosis
• A Phase III, Randomized, Double-blind Study to Evaluate Pembrolizumab plus Chemotherapy vs Placebo plus Chemotherapy as Neoadjuvant Therapy … Ended
  2022-501382-49-00 5 2017-03-07 Triple Negative Breast Cancer (TNBC)
• A phase I/II multicenter trial evaluating the association of hypofractionated stereotactic radiation therapy and the anti-PD-L1 Durvalumab ( … Ended
  2024-515000-39-00 9 2017-01-17 Recurrent glioblastoma.
• Tepotinib Phase II study in advanced lung cancer harboring MET exon 14 (METex14) skipping alterations and MET amplification Ended
  2024-512003-39-00 4 2016-07-18 Lung Cancer
• A Phase III Prospective Double Blind Placebo Controlled Randomized Study of Adjuvant MEDI4736 in Completely Resected Non-Small Cell Lung Can … Ended
  2024-517856-36-00 5 2015-03-09 Completely resected primary stage IB (≥ 4cm), II and IIIA non-small ce

Showing 625–648 of 653 trials